China-based Bio-Thera Pharmaceuticals (Bio-Thera) announced on 25 November 2020 that it had submitted an application for its proposed bevacizumab biosimilar, BAT1706, to the European Medicines Agency (EMA).And one viagra samples uk such chemical is the cyclic GMP. Possible Treatments to Deal with ED purchase cheap levitra s: This is one of the first and foremost medicines for erectile dysfunction treatment offer 20 mg of vardenafil at affordable prices. Later, the scientists of this reputed pharmacy observed major requirements and complaints of ED patients (especially the old age men) and side effects of viagra invented two more versions of this traditional herb. Revitalized reproductive organs help to cost viagra online produce more semen and sperms.
Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.
The announcement follows positive results that were reported by Bio-Thera from a phase III trial of BAT1706 back in February 2020. The company reported that the phase III clinical trial comparing the safety and efficacy of BAT1706 versus the originator biological Avastin (bevacizumab) had met its primary endpoint and that ‘the trial demonstrated equivalence in overall response rate (ORR) for the first-line treatment of patients with non-squamous non-small cell lung cancer’ [1].
An application for BAT1706 for the treatment of metastatic carcinoma of the colon or rectum and non-small cell lung cancer is also currently under review by China’s National Medicinal Product Administration.
The company also said that it intends to submit an application for BAT1706 to the US Food and Drug Administration ‘before the end of 2020’.
BAT1706 is Bio-Thera’s second such product. The company also gained approval in China for a copy biological, Qletli (格乐立) (adalimumab) in December 2019 [2].
The company is also developing several other proposed copy biologicals, including golimumab [1], ustekinumab [2], tocilizumab [1], secukinumab and mepolizumab, among others.